文献速递临床生化临床免疫分子诊断

1型糖尿病代谢组学与多组学:当前应用、局限与未来方向——叙述性综述

Type 1 diabetes metabolomics and multi-omics: Current applications, limitations, and future directions - A narrative review.
PubMed 文献 · Clin Chim Acta · 2026-10-17

本文为叙述性综述,总结代谢组学在1型糖尿病(T1DM)中的应用。T1DM进展伴随动态代谢紊乱,部分研究报道在临床发病或自身抗体阳性前可检测到代谢物改变。UPLC-MS和NMR等平台支持候选生物标志物发现,但现有证据多来自观察性队列的关联,尚需因果机制阐明、方法标准化、多人群验证及多组学纵向整合。

要点

  • 代谢组学可揭示T1DM相关代谢紊乱,部分改变或早于临床发病或自身抗体阳性。
  • UPLC-MS与NMR等平台为候选生物标志物发现提供高分辨率支持。
  • 现有发现多为观察性关联,尚不能作为经验证的早期检测工具。

核心结论

  • 代谢组学有望识别T1DM相关代谢失调,但需超越描述性分析,走向标准化和验证的代谢标志物并嵌入多组学与纵向框架。

研究设计与样本

  • 叙述性综述,总结代谢组学及多组学在T1DM中的应用、局限与未来方向。

主要发现

  • T1DM从自身抗体血清转换到显性糖尿病伴随动态代谢扰动,与血糖标志物相关并提供基因-环境交互和疾病异质性整合特征。
  • 部分研究报告在临床发病或自身抗体阳性前可检测到代谢物改变。
  • 靶向和非靶向方法可全面分析疾病相关代谢通路,但发现多反映观察性队列的关联而非经验证的早期检测工具。

临床怎么用

  • 代谢组学候选标志物在进一步验证前不宜用于T1DM早期诊断或临床决策。

局限性

  • 需阐明因果机制、标准化方法学、在多人群中验证发现,并将代谢组学与其他组学平台整合于稳健的纵向设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by immune-mediated destruction of pancreatic β-cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin. This disease, if not treated, leads to acute and chronic complications affecting the cardiovascular, renal, and retinal systems and introduces significant psychosocial burdens. But even with advances in insulin therapy, optimal glycemic control remains difficult to achieve. T1DM progression spans from autoantibody seroconversion to overt diabetes, accompanied by dynamic metabolic perturbations, contributing to β-cell dysfunction. These metabolic alterations correlate with glycemic markers and provide integrated signatures of gene-environment interactions and disease heterogeneity. Therefore, metabolomics has emerged as a promising approach for identifying metabolic dysregulation associated with T1DM, with some studies reporting metabolite alterations detectable before clinical onset or autoantibody positivity; targeted and untargeted approaches enable comprehensive profiling of disease-associated metabolic pathways, although these findings largely reflect associations from observational cohorts rather than validated early-detection tools. Here, the analysis of biofluids with advanced platforms such as UPLC-MS and NMR provides high-resolution insights into systemic metabolism, supporting the discovery of candidate biomarkers that may, pending further validation, contribute to earlier diagnosis and precision medicine strategies in T1DM. Even though current metabolomic studies have substantially improved the classification of metabolic alterations associated with T1DM, the field still necessitates clarification of causal mechanisms, standardization of methodologies, validation of findings across diverse populations, and integration of metabolomics with other omics platforms in robust longitudinal designs. These gaps highlight a clear necessity of moving beyond descriptive profiling toward systematically standardized and validated metabolomic markers embedded within multi-omics and longitudinal frameworks.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Abugabr Elhag HEE, Al-Sulaiti H. Type 1 diabetes metabolomics and multi-omics: Current applications, limitations, and future directions - A narrative review. Clin Chim Acta. 2026. PMID: 42887666. doi:10.1016/j.cca.2026.122900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。